Context Therapeutics is trading at $0.21, up 5.60% in pre-market, with no new company-specific announcement identified to explain the November 5 move. - The latest identified company news was the September CT-202 trial update. - Biotech-sector context was supportive, with XBI up 2.08% pre-market. - Amgen reported better-than-expected quarterly results and raised full-year guidance, offering industry context rather than a CNTX-specific catalyst.